Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials fo… Read more
Market Cap & Net Worth: Cyclo Therapeutics Inc (CYTH)
Cyclo Therapeutics Inc (NASDAQ:CYTH) has a market capitalization of $23.59 Million ($23.59 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29349 globally and #9733 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclo Therapeutics Inc's stock price $0.72 by its total outstanding shares 32736300 (32.74 Million).
Cyclo Therapeutics Inc Market Cap History: 2015 to 2025
Cyclo Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $1.80 Billion to $23.59 Million (-38.23% CAGR).
Cyclo Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclo Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.94x
Cyclo Therapeutics Inc's market cap is 17.94 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.80 Billion | $950.46K | -$2.55 Million | 1894.35x | N/A |
| 2016 | $1.41 Billion | $1.50 Million | -$4.22 Million | 936.62x | N/A |
| 2017 | $1.15 Billion | $1.24 Million | -$3.83 Million | 925.68x | N/A |
| 2018 | $2.62 Billion | $1.01 Million | -$4.26 Million | 2589.19x | N/A |
| 2019 | $1.11 Billion | $1.01 Million | -$7.67 Million | 1105.08x | N/A |
| 2020 | $142.40 Million | $903.38K | -$8.92 Million | 157.63x | N/A |
| 2021 | $130.95 Million | $1.59 Million | -$14.31 Million | 82.58x | N/A |
| 2022 | $46.49 Million | $1.38 Million | -$15.28 Million | 33.79x | N/A |
| 2023 | $52.05 Million | $1.08 Million | -$20.06 Million | 48.36x | N/A |
| 2024 | $19.31 Million | $1.08 Million | -$20.06 Million | 17.94x | N/A |
Competitor Companies of CYTH by Market Capitalization
Companies near Cyclo Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Cyclo Therapeutics Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Cyclo Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Cyclo Therapeutics Inc's market cap moved from $1.80 Billion to $ 23.59 Million, with a yearly change of -38.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $23.59 Million | +22.14% |
| 2024 | $19.31 Million | -62.89% |
| 2023 | $52.05 Million | +11.97% |
| 2022 | $46.49 Million | -64.50% |
| 2021 | $130.95 Million | -8.05% |
| 2020 | $142.40 Million | -87.21% |
| 2019 | $1.11 Billion | -57.50% |
| 2018 | $2.62 Billion | +128.57% |
| 2017 | $1.15 Billion | -18.60% |
| 2016 | $1.41 Billion | -21.82% |
| 2015 | $1.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cyclo Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.59 Million USD |
| MoneyControl | $23.59 Million USD |
| MarketWatch | $23.59 Million USD |
| marketcap.company | $23.59 Million USD |
| Reuters | $23.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.